Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Kodiak Sciences Inc KOD

Healthcare Biotechnology
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:KOD)

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

PR Newswire March 28, 2024

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

PR Newswire March 26, 2024

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

PR Newswire January 30, 2024

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire January 4, 2024

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

PR Newswire November 21, 2023

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

PR Newswire November 14, 2023

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

PR Newswire November 6, 2023

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

PR Newswire November 1, 2023

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

PR Newswire October 11, 2023
View More News ››

Opinion & Analysis (NDAQ:KOD)

Kodiak Shares Soar on $225 Million Royalty Deal for Retinal Drug

Streetwise Reports December 3, 2019
View More Opinion ››

Bullboard Posts (NDAQ:KOD)

THE UNRAVELLING OF KODIAK SCIENCES

$KOD   Kodiak Sciences, Inc. (NASDAQ: KOD), a clinical-stage biotechnology Company focused on creating novel therapeutics for...
AviseAnalytics - February 25, 2022

nice trend

TJPatrol1 - June 10, 2020
View more Bullboard ››

Slam Exploration Ltd

Slam Exploration Ltd

SLAM Exploration Ltd. is a Canadian junior resource company holding a portfolio of gold and base metal projects. The Company ...
View More »